← Back to headlines
J&J Dips Despite Positive Outlook; AstraZeneca and Spero Secure China Deals
Johnson & Johnson's stock experienced a dip despite an upbeat outlook, while AstraZeneca and Spero Therapeutics announced new deals in China.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
